MX2023005435A - Conjugados de monocuerpo-farmaco selectivos de macropinocitosis. - Google Patents

Conjugados de monocuerpo-farmaco selectivos de macropinocitosis.

Info

Publication number
MX2023005435A
MX2023005435A MX2023005435A MX2023005435A MX2023005435A MX 2023005435 A MX2023005435 A MX 2023005435A MX 2023005435 A MX2023005435 A MX 2023005435A MX 2023005435 A MX2023005435 A MX 2023005435A MX 2023005435 A MX2023005435 A MX 2023005435A
Authority
MX
Mexico
Prior art keywords
drug conjugates
macropinocytosis
selective
monobody
directed
Prior art date
Application number
MX2023005435A
Other languages
English (en)
Inventor
Craig Ramirez
Andrew Hauser
Dafna Bar-Sagi
Akiko Koide
Shohei Koide
Nathan Beals
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of MX2023005435A publication Critical patent/MX2023005435A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se refiere a composiciones farmacéuticas y de diagnóstico que comprenden conjugados de proteína-fármaco no enlazantes selectivos de macropxinocitosis. Estos conjugados de proteína-fármaco no enlazantes comprenden un dominio de fibronectina tipo III (FN3) no enlazante acoplado a un resto farmacéuticamente activo o a un resto de diagnóstico. La divulgación también se refiere a métodos de tratamiento y diagnostico que implican la administración de las composiciones farmacéuticas descritas en el presente documento a un sujeto necesitado.
MX2023005435A 2020-11-10 2021-11-10 Conjugados de monocuerpo-farmaco selectivos de macropinocitosis. MX2023005435A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112039P 2020-11-10 2020-11-10
PCT/US2021/058807 WO2022103856A1 (en) 2020-11-10 2021-11-10 Macropinocytosis selective monobody-drug conjugates

Publications (1)

Publication Number Publication Date
MX2023005435A true MX2023005435A (es) 2023-08-08

Family

ID=81601657

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005435A MX2023005435A (es) 2020-11-10 2021-11-10 Conjugados de monocuerpo-farmaco selectivos de macropinocitosis.

Country Status (8)

Country Link
US (1) US20240016944A1 (es)
EP (1) EP4243874A4 (es)
JP (1) JP2023551388A (es)
CN (1) CN116829192A (es)
AU (1) AU2021377232A1 (es)
CA (1) CA3198138A1 (es)
MX (1) MX2023005435A (es)
WO (1) WO2022103856A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213251B2 (en) * 2000-10-16 2007-06-14 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
CA2710835A1 (en) * 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
MX2010008874A (es) * 2008-02-14 2010-09-22 Bristol Myers Squibb Co Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
EP3173424A1 (en) * 2008-05-02 2017-05-31 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
AR071874A1 (es) * 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
AU2009308935B2 (en) 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
KR20110112301A (ko) * 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
WO2010096394A2 (en) * 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9522951B2 (en) * 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
EP2780364A2 (en) * 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
ES2781207T3 (es) * 2015-09-23 2020-08-31 Bristol Myers Squibb Co Dominios de fibronectina de tipo iii de unión a seroalbúmina con velocidad de disociación rápida
EP3471750A4 (en) * 2016-06-21 2020-02-26 Janssen Biotech, Inc. CYSTEINE-MODIFIED TYPE III FIBRONECTIN BINDING MOLECULES

Also Published As

Publication number Publication date
JP2023551388A (ja) 2023-12-08
US20240016944A1 (en) 2024-01-18
EP4243874A4 (en) 2024-10-16
CN116829192A (zh) 2023-09-29
WO2022103856A1 (en) 2022-05-19
AU2021377232A1 (en) 2023-06-15
CA3198138A1 (en) 2022-05-19
EP4243874A1 (en) 2023-09-20
AU2021377232A9 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
EP4223316A3 (en) Improved antibody-oligonucleotide conjugate
NZ602675A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP1289559B1 (de) Kombinationen von enzyminhibitoren umfassende zubereitungen und deren verwendung
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
RU2011119643A (ru) Фармацевтические композиции с уменьшенным высвобождением фенольных опиоидов
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MX2020011295A (es) Tratamiento de dermatitis atopica.
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
GB2456475A (en) Composition for the treatment of skin conditions
MX2024002561A (es) Combinaciones farmaceuticas que comprenden un inhibidor de tead y usos de las mismas para el tratamiento de canceres.
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2023013515A (es) Inhibidores de la interaccion de menina-mll.
EA201070315A1 (ru) Жидкая лекарственная форма конъюгата
ATE414522T1 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
RU2010141697A (ru) Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями
MX2023005435A (es) Conjugados de monocuerpo-farmaco selectivos de macropinocitosis.
MX2023005462A (es) Compuestos macrociclicos y metodos para usarlos.
Hattori et al. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
MD2516C2 (ro) Remediu medicamentos antiinflamator, antiseptic şi antifungic sub formă de gel
WO2019222130A8 (en) Combination treatment with antibody-drug conjugates and flt3 inhibitors